ASEAN Mutual Recognition Arrangement for Bioequivalence Study Reports of Generic Medicinal Products
ASEAN Mutual Recognition Arrangement for Bioequivalence Study Reports of Generic Medicinal Products

The ASEAN Secretariat
Jakarta
The Association of Southeast Asian Nations (ASEAN) was established on 8 August 1967. The Member States of the Association are Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand and Viet Nam. The ASEAN Secretariat is based in Jakarta, Indonesia.

For inquiries, contact:
The ASEAN Secretariat
Community Relations Division (CRD)
70A Jalan Sisingamangaraja
Jakarta 12110
Indonesia
Phone: (62 21) 724-3372, 726-2991
Fax: (62 21) 739-8234, 724-3504
E-mail: public@asean.org

Catalogue-in-Publication Data

ASEAN Mutual Recognition Arrangement for Bioequivalence Study Reports of Generic Medicinal Products
Jakarta: ASEAN Secretariat, October 2018

615.32
1. ASEAN – MRA – Sectoral MRA
2. ATIGA – Healthcare - Medicinal


ASEAN: A Community of Opportunities

The text of this publication may be freely quoted or reprinted, provided proper acknowledgement is given and a copy containing the reprinted material is sent to the Community Relations Division (CRD) of the ASEAN Secretariat, Jakarta

General information on ASEAN appears online at the ASEAN Website: www.asean.org

Copyright Association of Southeast Asian Nations (ASEAN) 2018.
All rights reserved.
ASEAN MUTUAL RECOGNITION ARRANGEMENT FOR BIOEQUIVALENCE STUDY REPORTS OF GENERIC MEDICINAL PRODUCTS

The Governments of Brunei Darussalam, the Kingdom of Cambodia, the Republic of Indonesia, the Lao People’s Democratic Republic, Malaysia, the Republic of Union of Myanmar, the Republic of the Philippines, the Republic of Singapore, the Kingdom of Thailand, and the Socialist Republic of Vietnam, Member States of the Association of Southeast Asian Nations (ASEAN) (hereinafter collectively referred to as “Member States” or singularly as “Member State”);

MINDFUL of the goals of establishing ASEAN as a single market and production base characterised by free flow of goods, services, investment, skilled labour and freer flow of capital envisaged in the ASEAN Charter, the Declaration on the ASEAN Economic Community Blueprint signed by the Leaders on 20 November 2007 in Singapore and the ASEAN Economic Community Blueprint 2025 adopted by the Leaders on 22 November 2015 in Kuala Lumpur, Malaysia;

RECALLING that the ASEAN Trade in Goods Agreement (“ATIGA”) signed on 26 February 2009 in Cha-am, Thailand has the objective of achieving free flow of goods in ASEAN as one of the principal means to establish a single market and production base for the deeper economic integration of the region towards the realisation of the ASEAN Economic Community;

RECALLING the ASEAN Framework Agreement on Mutual Recognition Arrangements signed on 16 December 1998 in Hanoi, Viet Nam to facilitate the elimination of technical barriers to trade and to enhance trade in ASEAN;

RECALLING the ASEAN Framework Agreement for the Integration of Priority Sectors and the ASEAN Sectoral Integration Protocol for Healthcare signed on 29 November 2004 in Vientiane, Lao PDR;
RECOGNISING that mutual recognition of results of conformity assessment procedures is an important means of reducing technical barriers to trade and that such mutual recognition is of particular interest to businesses in ASEAN;

MINDFUL of the different levels of infrastructure for technical regulation, standards, certification, inspection and analysis and of the different levels of economic development of Member States;

REITERATING that Member States' commitments under the World Trade Organization (WTO) Agreement on Technical Barriers to Trade (“TBT Agreement”) are reaffirmed in ATIGA and that Members are encouraged to enter into negotiations or consultations on mutual recognition of conformity assessment procedures which include, inter alia, procedures for sampling, testing, inspection, certification, registration, accreditation and for recognition of equivalence of technical regulations;

DESIRING to establish a Sectoral Mutual Recognition Arrangement for Bioequivalence Study Reports of Generic Medicinal Products (hereinafter referred to as “Sectoral MRA”) to facilitate the movement of generic medicinal products in ASEAN.

HAVE AGREED AS FOLLOWS:

ARTICLE 1
DEFINITIONS

For the purposes of this Sectoral MRA, the terms “standard” and “conformity assessment procedures”, shall, when used in this Sectoral MRA, have the same meaning as given in the definitions in the TBT Agreement. In addition, the following definitions shall apply:

a. “accept” means the use of bioequivalence study reports from listed Bioequivalence Centres as part of the requirements for the registration of generic medicinal products by the National Drug Regulatory Authority of a Member State taking into consideration that the review and assessment is under the jurisdiction of the respective Member States;

b. “Bioequivalence Centre” or “BE Centre” means any independent organisation located in the territory of the Member State which conducts the bioequivalence study and issues the bioequivalence study report;
c. “Bioequivalence Study” or “BE Study” means a comparative bioavailability study designed to establish equivalence between a generic medicinal product and a comparator product. Both the clinical and bioanalytical parts of the study must be conducted in Member States;

d. “Bioequivalence Study Report” or “BE Study Report” means a report of the BE study issued by 3 Listed BE Centre according to the ASEAN BE Study Reporting Format;

e. “comparator product” means a pharmaceutical product selected based on the selection criteria of a ASEAN comparator product with which the generic medicinal product is intended to be interchangeable in clinical practice, and it does not refer to any harmonised list of comparator products;

f. “generic medicinal product” means a product which has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the comparator product, and whose bioequivalence with the comparator product has been demonstrated by appropriate bioavailability studies;

g. “Listed Bioequivalence Centre” or “Listed BE Centre” means a BE Centre which has been recognised by the Joint Sectoral Committee;

h. “National Drug Regulatory Authority” or “NDRA”, in relation to each Member State, means the regulatory authority or entity of that Member State which exercises a legal right to control the import, manufacture, export, distribution, transfer, use and sale of medicinal products within that Member State’s jurisdiction and which may take regulatory action to ensure that the products marketed within its jurisdiction comply with regulatory requirements;

i. “Panel of Experts” or “PoE”, means a group of people with expertise in BE inspection who is appointed by the Joint Sectoral Committee. The PoE shall comprise the representatives from Member States’ NDRA; and

j. “Pharmaceutical Product Working Group” means the working group that was set up in the 13th Meeting of the ASEAN Consultative Committee on Standards and Quality held on 18-19 March 1999 in Manila, Philippines.
ARTICLE 2
OBJECTIVE

The objective of this Sectoral MRA is to enable the mutual recognition of BE Study Reports of generic medicinal products, issued by Listed BE Centres located in the territory of Member States in order to facilitate the movement of generic medicinal products within ASEAN.

ARTICLE 3
GENERAL PROVISIONS

1. All Member States shall be eligible for participation in this Sectoral MRA;

2. Member States shall ensure that the BE Study Report which is produced in accordance with ANNEX B (ASEAN Guideline for the Conduct of Bioequivalence Studies) and issued by a Listed BE Centre, is accepted for review;

3. Each Member State may establish a list of comparator products as guided by ANNEX B (ASEAN Guideline for the Conduct of Bioequivalence Studies). Each Member State is encouraged to publish this list on its website.

ARTICLE 4
SCOPE

This Sectoral MRA applies to BE Study Reports of generic medicinal products as defined in ANNEX A (Scope of Application of the Sectoral MRA), issued by Listed BE Centres located in the territory of Member States.

ARTICLE 5
JOINT SECTORAL COMMITTEE (JSC)

1. A JSC shall be established and shall be responsible for the effective functioning of this Sectoral MRA;
2. The JSC shall comprise one official representative from each Member State’s NDRA. The representative may be accompanied by his/her delegation at meetings of the JSC. For the purpose of membership of the JSC, a Member State shall notify the ASEAN Secretariat of the name of the official representative or his/her official designate;

3. The JSC shall be responsible for:

   a. establishing a PoE, that shall consist of NDRA officials, and establishing its terms of reference including the competencies and qualifications of individuals in the PoE;

   b. establishing requirements for the competencies and qualifications of independent experts, who shall not be members of the PoE, and who shall be appointed when necessary;

   c. preparing the requirements and procedures for the listing, verification and removal/de—listing of BE Centres in accordance with this Sectoral MRA;

   d. providing a forum for discussion of issues that may arise concerning the implementation of this Sectoral MRA;

   e. proposing amendments to this Sectoral MRA, including its annexes, and proposing additional annexes; and

   f. considering any other matters and taking appropriate technical decisions relating to the implementation of this Sectoral MRA.

4. The JSC shall endeavour to meet at least once a year as and when required, to discharge its duties and determine its own rules of procedures. Decisions of the JSC shall be made by consensus.

**ARTICLE 6
MUTUAL RECOGNITION OBLIGATIONS**

1. Member States shall accept the BE Study Reports issued by Listed BE Centres for review by their respective NDRAs;
2. The review and assessment of the BE Study Reports remains within the jurisdiction of Member States’ NDRAs.

ARTICLE 7
NATIONAL DRUG REGULATORY AUTHORITY (NDRA)

1. Each Member State shall designate an NDRA which is responsible for the implementation of the Member State’s obligations under this Sectoral MRA;

2. Member States shall notify the ASEAN Secretariat of the names of their NDRA official representatives or official designates and update the ASEAN Secretariat of any changes;

3. Each Member State shall ensure that its NDRA is authorised to implement the provisions of this Sectoral MRA;

4. The NDRA of each Member State shall be responsible for ensuring that any BE Centre within its jurisdiction that requests to be listed under this Sectoral MRA complies with all the requirements for listing before submitting the application to the JSC;

5. The NDRA of each Member State shall be responsible for monitoring the performance of its Listed BE Centres and shall notify the JSC of any non-compliance that it observes.

ARTICLE 8
LISTING OF BIOEQUIVALENCE CENTRES

1. An application for the listing of any BE Centre shall be submitted to the JSC, by an NDRA where the BE Centre is located;

2. The inspection of the BE Centre shall be conducted by the PoE. The JSC will make its decision for listing of BE Centre based on the recommendations from the PoE;
3. The ASEAN Secretariat shall update and maintain the list of Listed BE Centres and publish it on the ASEAN website.

**ARTICLE 9**
**TRANSPARENCY**

1. Each Member State shall designate a contact point for exchange of information and notify the ASEAN Secretariat of its designated contact point. The ASEAN Secretariat shall establish, update and maintain the list of contact points for all Member States;

2. Member States are encouraged to publish a list of their Listed BE Centres in their respective territories;

3. Each Member State may request information regarding a Listed BE Centre from the Member State where that Listed BE Centre is located.

**ARTICLE 10**
**IMPLEMENTATION**

1. Member States shall undertake appropriate measures to fulfil their obligations arising from this Sectoral MRA;

2. Member States shall implement the mutual recognition obligations referred to in Article 6 no later than five (5) years after the entry into force of this Sectoral MRA.

**ARTICLE 11**
**ANNEXES TO THE SECTORAL MRA**

1. Each Member State shall adhere to the following Annexes of this Sectoral MRA;

   a. ANNEX A (Scope of Application of the Sectoral MRA); and

   b. ANNEX B (ASEAN Guideline for the Conduct of Bioequivalence Studies)
1. Subject to the provisions of this Sectoral MRA, nothing in this Sectoral MRA shall be construed to:

a. limit the authority of a Member State to determine, through its legislative and administrative measures, the level of protection it considers appropriate for the safety and protection of the health of persons in its territory; and

b. limit the authority of the NDRA to take any appropriate and immediate measures whenever it ascertains that a generic medicinal product may:

i. compromise the health and safety of persons in its territory;

ii. not meet the legislative or administrative provisions of this Sectoral MRA; or

iii. fail to satisfy a requirement of this Sectoral MRA.

2. If the NDRA of a Member State takes a measure pursuant to paragraph 1, it shall inform all other NDRAs of the measure taken and, provide reasons thereof.

ARTICLE 13
CONFIDENCE BUILDING

Member States shall, through their contact points, strengthen and enhance existing cooperation through information exchange on regulatory requirements, conformity assessment procedures and regimes, and through confidence building measures.
ARTICLE 14
CONFIDENTIALITY

1. Member States shall maintain, to the extent permitted under their laws and regulations, the confidentiality of information exchanged under this Sectoral MRA;

2. Member States shall take all precautions reasonably necessary to protect information exchanged under this Sectoral MRA from unauthorised disclosure.

ARTICLE 15
SETTLEMENT OF DISPUTES

1. Member States shall at all times endeavour to agree on the interpretation or implementation of this Sectoral MRA and shall make any attempt through communication, dialogue, consultation and cooperation to arrive at a mutually satisfactory resolution of any matter that might affect the implementation of this Sectoral MRA;

2. The ASEAN Protocol on Enhanced Dispute Settlement Mechanism, signed on 29 November 2004 in Vientiane, Lao PDR and amendments thereto, shall apply to disputes concerning the interpretation or implementation of any of the provisions under this Sectoral MRA.

ARTICLE 16
RIGHTS AND OBLIGATIONS UNDER EXISTING INTERNATIONAL AGREEMENTS AND CONVENTIONS

This Sectoral MRA or any actions taken pursuant to this Sectoral MRA shall not affect the rights and obligations of any Member State under any existing international agreements or conventions to which it is also a signatory or party.
ARTICLE 17
REVIEW

This Sectoral MRA may be reviewed five (5) years after its entry into force or otherwise as appropriate for the purpose of fulfilling the objective of this Sectoral MRA.

ARTICLE 18
AMENDMENTS

1. The provisions of this Sectoral MRA may only be amended by mutual written agreement of all the Member States. Any amendment shall enter into force on such date as shall be mutually agreed upon by all Member States;

2. Notwithstanding paragraph 1 of this Article, amendments may be made to the Annexes to this Sectoral MRA by the endorsement of Pharmaceutical Product Working Group. Such amendments shall be administratively annexed to this Sectoral MRA and shall form an integral part of this Sectoral MRA;

3. Any amendment shall not prejudice the rights and obligations of the Member States arising from or based on this Sectoral MRA before the entry into force of such amendment.

ARTICLE 19
ENTRY INTO FORCE

This Sectoral MRA shall enter into force on the date of its signature.

ARTICLE 20
RESERVATIONS

No reservations shall be made with respect to any of the provisions of this Sectoral MRA.
ARTICLE 21
DEPOSITARY

This Sectoral MRA shall be deposited with the Secretary General of ASEAN, who shall promptly furnish a certified copy thereof to each Member State.

IN WITNESS WHEREOF, the undersigned, being duly authorised by their respective Governments, have signed this ASEAN Sectoral Mutual Recognition Arrangement for Bioequivalence Study Reports of Generic Medicinal Products.

DONE at Manhattan, Philippines, this Second day of November in the Year Two Thousand and Seventeen, in a single copy in the English Language.

For Brunei Darussalam:

LIM JOCK SENG
Minister at the Prime Minister’s Office and Second Minister of Foreign Affairs and Trade

For the Kingdom of Cambodia:

PAN SORASAK
Minister of Commerce
For the Republic of Indonesia:

ENGGARTIASTO LUKITA
Minister of Trade

For the Lao People’s Democratic Republic:

KHEMMANI PHOLSENA
Minister of Industry and Commerce

For Malaysia:

MUSTAPA MOHAMED
Minister of International Trade and Industry

For the Republic of the Union of Myanmar:

KYAW WIN
Union Minister for Planning and Finance
For the Republic of the Philippines:

RAMON M. LOPEZ  
Secretary of Trade and Industry

For the Republic of Singapore:

LIM HNG KIANG  
Minister for Trade and Industry (Trade)

For the Kingdom of Thailand:

APIRADI TANTRAPORN  
Minister of Commerce

For the Socialist Republic of Viet Nam:

TRAN TUAN ANH  
Minister of Industry and Trade
ANNEX A

The ASEAN Mutual Recognition Arrangement for Bioequivalence Study Reports of Generic Medicinal Products applies only to the following:

- Immediate-release, oral, solid dosage forms, with systemic actions
ANNEX B

ASEAN GUIDELINE FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES
# TABLE OF CONTENTS

**EXECUTIVE SUMMARY** ................................................................. 20

1. **INTRODUCTION** .................................................................................. 20
   1.1 **BACKGROUND** .................................................................................. 20
   1.2 **GENERIC MEDICINAL PRODUCTS** .................................................. 20
   1.3 **OTHER TYPES OF APPLICATION** .................................................... 21

2. **SCOPE** ................................................................................................... 21

3. **MAIN GUIDELINE TEXT** ....................................................................... 23
   3.1 **DESIGN, CONDUCT AND EVALUATION OF BIOEQUIVALENCE STUDIES** ....................................................................... 23
       3.1.1 Study design .................................................................................. 23
       3.1.2 Comparator and test product ......................................................... 24
       3.1.3 Subjects ........................................................................................ 26
       3.1.4 Study conduct ............................................................................... 28
       3.1.5 Characteristics to be investigated .................................................. 31
       3.1.6 Strength to be investigated ............................................................. 33
       3.1.7 Bioanalytical methodology ............................................................. 36
       3.1.8 Evaluation ...................................................................................... 37
       3.1.9 Narrow therapeutic index drugs ..................................................... 41
       3.1.10 Highly variable drugs or drug products ........................................... 42

   3.2 **IN VITRO DISSOLUTION TESTS** ..................................................... 43
       3.2.1 In vitro dissolution tests complementary to bioequivalence studies ...... 43
       3.2.2 In vitro dissolution tests in suppod of biowaiver of strengths ................. 43

   3.3 **STUDY REPORT** .............................................................................. 44
       3.3.1 Bioequivalence study report ............................................................. 44
       3.3.2 Other data to be included in an application ...................................... 44

   3.4 **VARIATION APPLICATIONS** .......................................................... 45

**DEFINITIONS** ............................................................................................. 45
APPENDIX I .................................................................................................................. 47
DISSOLUTION TESTING AND SIMILARITY OF DISSOLUTION PROFILES .......................................................... 47

APPENDIX II .................................................................................................................. 50
BIOEQUIVALENCE STUDY REQUIREMENTS FOR DIFFERENT DOSAGE FORM .................................................. 50

APPENDIX III ............................................................................................................... 55
BCS-BASED BIOWAIVER ............................................................................................... 55

APPENDIX IV ................................................................................................................. 60
ASEAN Bioequivalence Study Reporting Format .............................................................................. 60
EXECUTIVE SUMMARY

This guideline specifies the requirements for the design, conduct, and evaluation of bioequivalence studies for immediate release dosage forms with systemic action.

1. INTRODUCTION

1.1 Background

Two medicinal products containing the same active substance are considered bioequivalent if they are pharmaceutically equivalent or pharmaceutical alternatives and their bioavailabilities (rate and extent) after administration in the same molar dose lie within acceptable predefined limits. These limits are set to ensure comparable in vivo performance, i.e. similarity in terms of safety and efficacy.

In bioequivalence studies, the plasma concentration time curve is generally used to assess the rate and extent of absorption. Selected pharmacokinetic parameters and preset acceptance limits allow the final decision on bioequivalence of the tested products. AUC, the area under the concentration time curve, reflects the extent of exposure. $C_{\text{max}}$, the maximum plasma concentration or peak exposure, and the time to maximum plasma concentration, $t_{\text{max}}$, are parameters that are influenced by absorption rate.

It is the objective of this guideline to specify the requirements for the design, conduct, and evaluation of bioequivalence studies. The possibility of using in vitro instead of in vivo studies is also addressed.

1.2 Generic medicinal products

In applications for generic medicinal products, the concept of bioequivalence is fundamental. The purpose of establishing bioequivalence is to demonstrate equivalence in biopharmaceutics quality between the generic medicinal product and a comparator medicinal product in order to allow bridging of preclinical tests and of clinical trials associated with the comparator medicinal product. A generic medicinal product is a product which has the same qualitative and quantitative composition in active substances and the same dosage form as the medicinal product, and whose bioequivalence with the comparator medicinal product has been demonstrated by appropriate bioavailability studies. The different salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of anactive substance are considered to be the
same active substance, unless they differ significantly in properties with regard to safety and/or efficacy.

1.3 Other types of application

Other types of applications may also require demonstration of bioequivalence, including variations, fixed combinations and extensions applications.

The recommendations on design and conduct given for bioequivalence studies in this guideline may also be applied to comparative bioavailability studies evaluating different formulations used during the development of a new medicinal product containing a new chemical entity and to comparative bioavailability studies included in extension that are not based exclusively on bioequivalence data.

2. SCOPE

This guideline focuses on recommendations for bioequivalence studies for immediate release formulations with systemic action. It also sets the relevant criteria under which bioavailability studies need not be required (either waiver for additional strength, see section 3.1.6. a specific type of formulation, see Appendix II or BCS based Biowaiver, see Appendix III).

Specific recommendations regarding bioequivalence studies for other products, e.g. Modified release products, transdermal products and orally inhaled products etc, refer to relevant guidelines as stated below.

The scope is limited to chemical entities. Recommendation for the comparison of biologicals to comparator medicinal products can be found in guidelines on similar biological medicinal products.

In case bioequivalence cannot be demonstrated using drug concentrations, in exceptional circumstances pharmacodynamic or clinical endpoints may be needed. This situation is outside the scope of this guideline and the reader is referred to therapeutic area specific guidelines.

Although the concept of bioequivalence possibly could be considered applicable for herbal medicinal products, the general principles outlined in this guideline are not applicable to herbal medicinal products, for which active constituents are less well defined than for chemical entities.
This guideline should be read in conjunction with other pertinent elements outlined in current and relevant guidelines and regulations including those on:

- General Considerations for Clinical Trials (ICH topic E8, CPMP/ICH/291/95);
- Guideline for Good Clinical Practice (ICH E6 (R1), CPMP/ICH/135/95);
- Statistical Principles for Clinical Trials (ICH E9, CPMP/ICH/363/96);
- Structure and Content of Clinical Study Reports (ICH E3, CPMP/ICH/137/95);
- Pharmacokinetic studies in man (Eudralex, Volume 3, 3CC3a);
- Modified Release Oral and Transdermal Dosage Forms: Sections I and II (CPMP/QWP/604/96, CPMP/EWP/280/96);
- Fixed Combination Medicinal Products (CPMP/EWP/240/95 Rev 1) Requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) (CPMP/EWP/4151/00 Rev 1);
- Clinical Requirements for Locally Applied, Locally Acting Products containing Known Constituents (CPMP/EWP/239/95);
- ASEAN Common Technical Dossier;
- ASEAN Analytical Validation Guidelines;
- Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to establish Interchangeability (WHO);
The guideline should also be read in conjunction with relevant guidelines on pharmaceutical quality. The test products used in the bioequivalence study must be prepared in accordance with GMP regulations.

3. MAIN GUIDELINE TEXT

3.1 Design, conduct and evaluation of bioequivalence studies

The number of studies and study design depend on the physico-chemical characteristics of the substance, its pharmacokinetic properties and proportionality in composition, and should be justified accordingly. In particular it may be necessary to address the linearity of pharmacokinetics, the need for studies both in fed and fasting state, the need for enantioselective analysis and the possibility of waiver for additional strengths (see sections 3.1.4, 3.1.5 and 3.1.6).

3.1.1 Study design

The study should be designed in such a way that the formulation effect can be distinguished from other effects.

Standard design

If two formulations are compared, a randomised, two-period, two-sequence single dose crossover design is recommended. The treatment periods should be separated by a wash out period sufficient to ensure that drug concentrations are below the lower limit of bioanalytical quantification in all subjects at the beginning of the second period. Normally at least 5 elimination half-lives are necessary to achieve this.

Alternative designs

Under certain circumstances, provided the study design and the statistical analyses are scientifically sound, alternative well-established designs could be considered such as parallel design for substances with very long half-life and replicate designs e.g. for substances with highly variable pharmacokinetic characteristics (see section 3.1.10).

Conduct of a multiple dose study in patients is acceptable if a single dose study cannot be conducted in healthy volunteers due to tolerability reasons. and a single dose study is not feasible in patients.
In the rare situation where problems of sensitivity of the analytical method preclude sufficiently precise plasma concentration measurements after single dose administration and where the concentrations at steady state are sufficiently high to be reliably measured, a multiple dose study may be acceptable as an alternative to the single dose study. However, given that a multiple dose study is less sensitive in detecting differences in $C_{\text{max}}$, this will only be acceptable if the applicant can adequately justify that the sensitivity of the analytical method cannot be improved and that it is not possible to reliably measure the parent compound after single dose administration taking into account also the option of using a supra-therapeutic dose in the bioequivalence study (see also section 3.1.6). Due to the recent development in the bioanalytical methodology, it is unusual that parent drug cannot be measured accurately and precisely. Hence, use of a multiple dose study instead of a single dose study, due to limited sensitivity of the analytical method, will only be accepted in exceptional cases.

In steady-state studies, the washout period of the previous treatment can overlap with the build-up of the second treatment, provided the build-up period is sufficiently long (at least 5 times the terminal half-life).

### 3.1.2 Comparator and test product

**Comparator Product**

Test products in an application for a generic product or an extension of a generic product are normally compared with the corresponding dosage form of a comparator product. The selection of comparator product should be based on the selection criteria of ASEAN comparator product as follows:

i. Innovator product and multiple manufacturing sites of the same innovator registered in the country is acceptable.

ii. If the innovator product used as comparator is not registered in the country, justification is required from the generic company to prove its interchangeability with the registered innovator (*in vitro* or *in vivo*).

iii. If the innovator product cannot be identified, the choice of comparator must be made carefully and be comprehensively justified by the applicant. The selection criteria of a comparator in order of preference are:
- Approval in ICH and associated countries
- Pre-qualified by WHO

A well selected comparator must conform to compendia quality standards, if applicable.

It is recommended to clarify with the regulatory authority regarding the choice of comparator product before the bioequivalence study is conducted. The selection of the batch of comparator product used in a bioequivalence study should be based on assay content and dissolution data and is the responsibility of the applicant. Unless otherwise justified, the assayed content of the batch used as test product should not differ more than 5% from that of the batch used as comparator product determined with the test procedure proposed for routine quality testing of the test product. Certificate of analysis (CoA) of the comparator product can be submitted to support that the assayed content of the batch used as test product does not differ more than 5% from the comparator batch. The Applicant should document how a representative batch of the comparator product with regards to dissolution and assay content has been selected. It is advisable to investigate more than one single batch of the comparator product when selecting comparator product batch for the bioequivalence study.

Test product

The test product used in the study should be representative of the product to be marketed and this should be discussed and justified by the applicant.

For example, for oral solid forms for systemic action:

a) The test product should usually originate from a batch of at least 1/10 of production scale or 100,000 units, whichever is greater, unless otherwise justified.

b) The production of batches used should provide a high level of assurance that the product and process will be feasible on an industrial scale. In case of a production batch smaller than 100,000 units, a full production batch will be required.

c) The characterisation and specification of critical quality attributes of the drug product, such as dissolution, should be established from the test batch, i.e. the clinical batch for which bioequivalence has been demonstrated.
d) Samples of the product from additional pilot and full scale production batches, submitted to support the application, shall be compared with those of the bioequivalence study test batch, and shall show similar in vitro dissolution profiles when employing suitable dissolution test conditions (see Appendix I).

Comparative dissolution profile testing shall be undertaken on the first three production batches. The results shall be provided at 3 Regulatory Authority’s request or if the dissolution profiles are not similar together with proposed action to be taken.

For other immediate release dosage forms for systemic action, justification of the representative nature of the test batch should be similarly established.

Packaging of study products

The comparator and test products should be packed in an individual way for each subject and period, either before their shipment to the trial site, or at the trial site itself. Packaging (including labeling) should be performed in accordance with good manufacturing practice.

It should be possible to identify unequivocally the identity of the product administered to each subject at each trial period. Packaging, labeling and administration of the products to the subjects should therefore be documented in detail. This documentation should include all precautions taken to avoid and identify potential dosing mistakes. The use of labels with a tear-off portion is recommended.

3.1.3 Subjects

Number of subjects

The number of subjects to be included in the study should be based on an appropriate sample size calculation.

For a standard two way crossover study, the number of subjects required is determined by:

a) the intra-subject coefficient of variation of the drug to be studied either estimated from a pilot study, results of previous clinical studies or from published literature;
b) the significance level desired (\(\alpha=0.05\));

c) the expected deviation from the comparator product ratio of T/R (delta between 5% to 10%);

d) the acceptance limit (should be in accordance with the respective sections in the guidance i.e. 3.1.8, 3.1.9 & 3.1.10);

d) the required statistical power of study should be at least 80%.

The clinical and analytical standards imposed may also influence the statistically determined number of subjects. However, generally the minimum number of subjects should not be smaller than 12.

**Selection of subjects**

The subject population for bioequivalence studies should be selected with the aim of permitting detection of differences between pharmaceutical products. In order to reduce variability not related to differences between products, the studies should normally be performed in healthy volunteers unless the drug carries safety concerns that make this unethical. This model, *in vivo* healthy volunteers, is regarded as adequate in most instances to detect formulation differences and to allow extrapolation of the results to populations for which the comparator medicinal product is approved (the elderly, children, patients with renal or liver impairment, etc.).

The inclusion/exclusion criteria should be clearly stated in the protocol. Subjects should be 18-55 years of age and preferably have a Body Mass Index between 18 and 30 kg/m\(^2\).

The subjects should be screened for suitability by means of clinical laboratory tests, a medical history, and a physical examination. Depending on the drug’s therapeutic class and safety profile, special medical investigations and precautions may have to be carried out before, during and after the completion of the study. Subjects could belong to either sex; however, the risk to women of childbearing potential should be considered. Subjects should preferably be non-smokers and without a history of alcohol or drug abuse. Phenotyping and/or genotyping of subjects may be considered for safety or pharmacokinetic reasons.

In parallel design studies, the treatment groups should be comparable in all known variables that may affect the pharmacokinetics of the active substance (e.g. age, body
weight, sex, ethnic origin, smoking status, extensive/poor metabolic status). This is an essential pre-requisite to give validity to the results from such studies.

If the investigated active substance is known to have adverse effects, and the pharmacological effects or risks are considered unacceptable for healthy volunteers, it may be necessary to include patients instead, under suitable precautions and supervision.

### 3.1.4 Study conduct

#### Standardisation

The test conditions should be standardised in order to minimise the variability of all factors involved except that of the products being tested. Therefore, it is recommended to standardise diet, fluid intake and exercise.

The time of day for ingestion should be specified. Subjects should fast for at least 8 hours prior to administration of the products, unless otherwise justified. As fluid intake may influence gastric passage for oral administration forms, the test and comparator products should be administered with a standardised volume of fluid (at least 150 ml). It is recommended that water is allowed as desired except for one hour before and one hour after drug administration and food is allowed no less than 4 hours after drug administration. Meals taken after dosing should be standardised in regard to composition and time of administration during an adequate period of time (e.g. 12 hours).

In case the study is to be performed during fed conditions, the timing of administration of the drug product in relation to food intake is recommended to be according to the SmPC of the originator product. If no specific recommendation is given in the originator SmPC, it is recommended that subjects should start the meal 30 minutes prior to administration of the drug product and eat this meal within 30 minutes.

As the bioavailability of an active moiety from a dosage form could be dependent upon gastrointestinal transit times and regional blood flows, posture and physical activity may need to be standardised.

The subjects should abstain from food and drinks, which may interact with circulatory, gastrointestinal, hepatic or renal function (e.g. alcoholic drinks or certain fruit juices such as grapefruit juice) during a suitable period before and during the study. Subjects should not take any other concomitant medication (including herbal remedies) for an
appropriate interval before as well as during the study. Contraceptives are, however, allowed. In case concomitant medication is unavoidable and a subject is administered other drugs, for instance to treat adverse events like headache, the use must be reported (dose and time of administration) and possible effects on the study outcome must be addressed. In rare cases, the use of a concomitant medication is needed for all subjects for safety or tolerability reasons (e.g. opioid antagonists, anti-emetics). In that scenario, the risk for a potential interaction or bioanalytical interference affecting the results must be addressed.

Medicinal products that according to the originator SmPC are to be used explicitly in combination with another product (e.g. certain protease inhibitors in combination with ritonavir) may be studied either as the approved combination or without the product recommended to be administered concomitantly.

In bioequivalence studies of endogenous substances, factors that may influence the endogenous baseline levels should be controlled if possible (e.g. strict control of dietary intake).

**Sampling times**

A sufficient number of samples to adequately describe the plasma concentration-time profile should be collected. The sampling schedule should include frequent sampling around predicted $t_{\text{max}}$ to provide a reliable estimate of peak exposure. In particular, the sampling schedule should be planned to avoid $C_{\text{max}}$ being the first point of a concentration time curve. The sampling schedule should also cover the plasma concentration time curve long enough to provide a reliable estimate of the extent of exposure which is achieved if $\text{AUC}_{[0-t]}$ covers at least 80% of $\text{AUC}_{(0-\infty)}$. At least three to four samples are needed during the terminal log—linear phase in order to reliably estimate the terminal rate constant (which is needed for a reliable estimate of $\text{AUC}_{(0-\infty)}$). $\text{AUC}$ truncated at 72 h ($\text{AUC}_{(0-72\text{h})}$) may be used as an alternative to $\text{AUC}_{(0-t)}$ for comparison of extent of exposure as the absorption phase has been covered by 72 h for immediate release formulations. A sampling period longer than 72 h is therefore not considered necessary for any immediate release formulation irrespective of the half life of the drug.

In multiple-dose studies, the pre-dose sample should be taken immediately before (within 5 minutes) dosing and the last sample is recommended to be taken within 10 minutes of the nominal time for the dosage interval to ensure an accurate determination of $\text{AUC}_{(0-t)}$. 
If urine is used as the biological sampling fluid, urine should normally be collected over no less than three times the terminal elimination half-life. However, in line with the recommendations on plasma sampling, urine does not need to be collected for more than 72 h. If rate of excretion is to be determined, the collection intervals need to be as short as feasible during the absorption phase (see also section 3.1.5).

For endogenous substances, the sampling schedule should allow characterisation of the endogenous baseline profile for each subject in each period. Often, a baseline is determined from 2-3 samples taken before the drug products are administered. In other cases, sampling at regular intervals throughout 1-2 day(s) prior to administration may be necessary in order to account for fluctuations in the endogenous baseline due to circadian rhythms (see section 3.1.5).

**Fasting or fed conditions**

In general, a bioequivalence study should be conducted under fasting conditions as this is considered to be the most sensitive condition to detect a potential difference between formulations. For products where the SmPC recommends intake of the comparator medicinal product on an empty stomach or irrespective of food intake, the bioequivalence study should hence be conducted under fasting conditions. For products where the SmPC recommends intake of the comparator medicinal product only in fed state, the bioequivalence study should generally be conducted under fed conditions.

However, for products with specific formulation characteristics (e.g. microemulsions, solid dispersions), bioequivalence studies performed under both fasted and fed conditions are required unless the product must be taken only in the fasted state or only in the fed state.

In cases where information is required in both the fed and fasted states, it is acceptable to conduct either two separate two-way cross over studies or a four-way cross-over study.

In studies performed under fed conditions, the composition of the meal is recommended to be according to the SmPC of the originator product. If no specific recommendation is given in the originator SmPC, the meal should be a high-fat (approximately 50 percent of total caloric content of the meal) and high-calorie (approximately 800 to 1000 kcal) meal. This test meal should derive approximately 150, 250, and 500-600 kcal from protein, carbohydrate, and fat, respectively.
The composition of the meal should be described with regard to protein, carbohydrate and fat content (specified in grams, calories and relative caloric content (%)).

3.1.5 Characteristics to be investigated

Pharmacokinetic parameters

Actual time of sampling should be used in the estimation of the pharmacokinetic parameters. In studies to determine bioequivalence after a single dose, $AUC_{[0-t]}$, $AUC_{[0-\infty]}$, $C_{\text{max}}$ and $t_{\text{max}}$ should be determined. In studies with a sampling period of 72 h, and where the concentration at 72 h is quantifiable, $AUC_{[0-\infty]}$ and residual area do not need to be reported; it is sufficient to report $AUC$ truncated at 72h, $AUC_{[0-72h]}$. Additional parameters that may be reported include the terminal rate constant, $\lambda_z$, and $t_{1/2}$.

In studies to determine bioequivalence for immediate release formulations at steady state, $AUC_{(0-t)}$, $C_{\text{max,ss}}$, and $t_{\text{max,ss}}$ should be determined.

When using urinary data, $Ae_{(0-t)}$ and $R_{\text{max}} = \left(\frac{dAe}{dt}\right)_{\text{max}}$ should be determined.

Non-compartmental methods should be used for determination of pharmacokinetic parameters in bioequivalence studies. The use of compartmental methods for the estimation of parameters is not acceptable.

Parent compound or metabolites

General recommendations

In principle, evaluation of bioequivalence should be based upon measured concentrations of the parent compound. The reason for this is that $C_{\text{max}}$ of a parent compound is usually more sensitive to detect differences between formulations in absorption rate than $C_{\text{max}}$ of a metabolite.

Inactive pro-drugs

Also for inactive prodrugs, demonstration of bioequivalence for parent compound is recommended. The active metabolite does not need to be measured. However, some pro-drugs may have low plasma concentrations and be quickly eliminated resulting in difficulties in demonstrating bioequivalence for parent compound. In this situation it is acceptable to demonstrate bioequivalence for the main active metabolite without measurement of parent compound. In the context of this guideline, a parent compound
can be considered to be an inactive pro-drug if it has no or very low contribution to clinical efficacy.

**Use of metabolite data as surrogate for active parent compound**

The use of a metabolite as a surrogate for an active parent compound is not encouraged. This can only be considered if the applicant can adequately justify that the sensitivity of the analytical method for measurement of the parent compound cannot be improved and that it is not possible to reliably measure the parent compound after single dose administration taking into account also the option of using a higher single dose in the bioequivalence study (see also section 3.1.6). Due to recent developments in bioanalytical methodology it is unusual that parent drug cannot be measured accurately and precisely. Hence, the use of a metabolite as a surrogate for active parent compound is expected to be accepted only in exceptional cases. When using metabolite data as a substitute for active parent drug concentrations, the applicant should present any available data supporting the view that the metabolite exposure will reflect parent drug and that the metabolite formation is not saturated at therapeutic doses.

**Enantiomers**

The use of achiral bioanalytical methods is generally acceptable. However, the individual enantiomers should be measured when all the following conditions are met:

1. the enantiomers exhibit different pharmacokinetics
2. the enantiomers exhibit pronounced difference in pharmacodynamics
3. the exposure (AUC) ratio of enantiomers is modified by a difference in the rate of absorption.

The individual enantiomers should also be measured if the above conditions are fulfilled or are unknown. If one enantiomer is pharmacologically active and the other is inactive or has a low contribution to activity, it is sufficient to demonstrate bioequivalence for the active enantiomer.

**The use of urinary data**

The use of urinary excretion data as a surrogate for a plasma concentration may be acceptable in determining the extent of exposure where it is not possible to reliably measure the plasma concentration-time profile of parent compound. However, the use of urinary data has to be carefully justified when used to estimate peak exposure. If
a reliable plasma $C_{\text{max}}$ can be determined, this should be combined with urinary data on the extent of exposure for assessing bioequivalence. When using urinary data, the applicant should present any available data supporting that urinary excretion will reflect plasma exposure.

**Endogenous substances**

If the substance being studied is endogenous, the calculation of pharmacokinetic parameters should be performed using baseline correction so that the calculated pharmacokinetic parameters refer to the additional concentrations provided by the treatment. Administration of supra-therapeutic doses can be considered in bioequivalence studies of endogenous drugs, provided that the dose is well tolerated. so that the additional concentrations over baseline provided by the treatment may be reliably determined. If a separation in exposure following administration of different doses of a particular endogenous substance has not been previously established this should be demonstrated, either in a pilot study or as part of the pivotal bioequivalence study using different doses of the comparator formulation, in order to ensure that the dose used for the bioequivalence comparison is sensitive to detect potential differences between formulations.

The exact method for baseline correction should be pre-specified and justified in the study protocol. In general, the standard subtractive baseline correction method, meaning either subtraction of the mean of individual endogenous pre-dose concentrations or subtraction of the individual endogenous predose AUC, is preferred. In rare cases where substantial increases over baseline endogenous levels are seen, baseline correction may not be needed.

In bioequivalence studies with endogenous substances, it cannot be directly assessed whether carryover has occurred, so extra care should be taken to ensure that the washout period is of an adequate duration.

**3.1.6 Strength to be investigated**

If several strengths of a test product are applied for, it may be sufficient to establish bioequivalence at only one or two strengths, depending on the proportionality in composition between the different strengths and other product related issues described below. The strength(s) to evaluate depends on the linearity in pharmacokinetics of the active substance.
In case of non-linear pharmacokinetics (i.e. not proportional increase in AUC with increased dose) there may be a difference between different strengths in the sensitivity to detect potential differences between formulations. In the context of this guideline, pharmacokinetics is considered to be linear if the difference in dose-adjusted mean AUCs is no more than 25% when comparing the studied strength (or strength in the planned bioequivalence study) and the strength(s) for which a waiver is considered. In order to assess linearity, the applicant should consider all data available in the public domain with regard to the dose proportionality and review the data critically.

If bioequivalence has been demonstrated at the strength(s) that are most sensitive to detect a potential difference between products, *in vivo* bioequivalence studies for the other strength(s) can be waived.

**General biowaiver criteria**

The following general requirements must be met where a waiver for additional strength(s) is claimed:

a) the pharmaceutical products are manufactured by the same manufacturing process;

b) the qualitative composition of the different strengths is the same;

c) the composition of the strengths are quantitatively proportional, i.e. the ratio between the amount of each excipient to the amount of active substance(s) is the same for all strengths (for immediate release products coating components, capsule shell, colour agents and flavours are not required to follow this rule);

If there is some deviation from quantitatively proportional composition, condition c is still considered fulfilled if condition i) and ii) or i) and iii) below apply to the strength used in the bioequivalence study and the strength(s) for which a waiver is considered:

i. the amount of the active substance(s) is less than 5 % of the tablet core weight, the weight of the capsule content;

ii. the amounts of the different core excipients or capsule content are the same for the concerned strengths and only the amount of active substance is changed;
iii. the amount of a filler is changed to account for the change in amount of active substances. The amounts of other core excipients or capsule content should be the same for the concerned strengths.

d) appropriate in vitro dissolution data should confirm the adequacy of waiving additional in vivo bioequivalence testing (see section 3.2).

Linear pharmacokinetics

For products where all the above conditions a) to d) are fulfilled, it is sufficient to establish bioequivalence with only one strength.

The bioequivalence study should in general be conducted at the highest strength. For products with linear pharmacokinetics and where the drug substance is highly soluble (see Appendix III), selection of a lower strength than the highest is also acceptable. Selection of a lower strength may also be justified if the highest strength cannot be administered to healthy volunteers for safety/tolerability reasons. Further, if problems of sensitivity of the analytical method preclude sufficiently precise plasma concentration measurements after single dose administration of the highest strength, a higher dose may be selected (preferably using multiple tablets of the highest strength). The selected dose may be higher than the highest therapeutic dose provided that this single dose is well tolerated in healthy volunteers and that there are no absorption or solubility limitations at this dose.

Non-linear pharmacokinetics

For drugs with non-linear pharmacokinetics characterised by a more than proportional increase in AUC with increasing dose over the therapeutic dose range, the bioequivalence study should in general be conducted at the highest strength. As for drugs with linear pharmacokinetics a lower strength may be justified if the highest strength cannot be administered to healthy volunteers for safety/tolerability reasons. Likewise a higher dose may be used in case of sensitivity problems of the analytical method in line with the recommendations given for products with linear pharmacokinetics above.

For drugs with a less than proportional increase in AUC with increasing dose over the therapeutic dose range, bioequivalence should in most cases be established both at the highest strength and at the lowest strength (or a strength in the linear range), i.e. in this situation two bioequivalence studies are needed. If the non-linearity is not caused by limited solubility but is due to e.g. saturation of uptake transporters and provided that conditions a) to d) above are fulfilled and the test and comparator products do not
contain any excipients that may affect gastrointestinal motility or transport proteins, it is sufficient to demonstrate bioequivalence at the lowest strength (or a strength in the linear range). Selection of other strengths may be justified if there are analytical sensitivity problems preventing a study at the lowest strength or if the highest strength cannot be administered to healthy volunteers for safety/tolerability reasons.

**Bracketing approach**

Where bioequivalence assessment at more than two strengths is needed, e.g. because of deviation from proportional composition, a bracketing approach may be used. In this situation it can be acceptable to conduct two bioequivalence studies, if the strengths selected represent the extremes, e.g. the highest and the lowest strength or the two strengths differing most in composition, so that any differences in composition in the remaining strengths is covered by the two conducted studies.

Where bioequivalence assessment is needed both in fasting and in fed state and at two strengths due to nonlinear absorption or deviation from proportional composition, it may be sufficient to assess bioequivalence in both fasting and fed state at only one of the strengths. Waiver of either the fasting or the fed study at the other strength(s) may be justified based on previous knowledge and/or pharmacokinetic data from the study conducted at the strength tested in both fasted and fed state. The condition selected (fasting or fed) to test the other strength(s) should be the one which is most sensitive to detect a difference between products.

**Fixed combinations**

The conditions regarding proportional composition should be fulfilled for all active substances of fixed combinations. When considering the amount of each active substance in a fixed combination the other active substance(s) can be considered as excipients. In the case of bilayer tablets, each layer may be considered independently.

**3.1.7 Bioanalytical methodology**

The bioanalytical part of bioequivalence trials should be conducted according to the applicable principles of Good Laboratory Practice (GLP). (EMA/OECD GLP/WHO GLP STANDARD ISO/IEC 17025/2005). If national GLP requirements are in accordance with Organisation for Economic Co-operation and Development (OECD), drug regulatory authority may conduct site inspection based on the OECD principle.
The bioanalytical methods used must be well characterised, fully validated and documented to yield reliable results that can be satisfactorily interpreted. Within study validation should be performed using Quality control samples in each analytical run.

The main characteristics of a bioanalytical method that is essential to ensure the acceptability of the performance and the reliability of analytical results are: selectivity, lower limit of quantitation, the response function (calibration curve performance), accuracy, precision and stability.

The lower limit of quantitation should be $1/20$ of $C_{max}$ or lower, as pre-dose concentrations should be detectable at 5% of $C_{max}$ or lower (see section 3.1.8. Carry-over effects).

Reanalysis of study samples should be predefined in the study protocol (and/or SOP) before the actual start of the analysis of the samples. Normally reanalysis of subject samples because of a pharmacokinetic reason is not acceptable. This is especially important for bioequivalence studies, as this may bias the outcome of such a study.

Analysis of samples should be conducted without information on treatment.

3.1.8 Evaluation

In bioequivalence studies, the pharmacokinetic parameters should in general not be adjusted for differences in assayed content of the test and comparator batch. However, in exceptional cases where a comparator batch with an assay content differing less than 5% from test product cannot be found (see section 3.1.2) content correction could be accepted. If content correction is to be used, this should be pre-specified in the protocol and justified by inclusion of the results from the assay of the test and reference products in the protocol.

Subject accountability

Ideally, all treated subjects should be included in the statistical analysis. However, subjects in a crossover trial who do not provide evaluable data for both of the test and comparator products (or who fail to provide evaluable data for the single period in a parallel group trial) should not be included.

The data from all treated subjects should be treated equally. it is not acceptable to have a protocol which specifies that ‘spare’ subjects will be included in the analysis only if needed as replacements for other subjects who have been excluded.
It should be planned that all treated subjects should be included in the analysis, even if there are no drop-outs.

In studies with more than two treatment arms (e.g. a three period study including two comparator, one from EU and another from USA, or a four period study including test and reference in fed and fasted states), the analysis for each comparison should be conducted excluding the data from the treatments that are not relevant for the comparison in question.

**Reasons for exclusion**

Unbiased assessment of results from randomised studies requires that all subjects are observed and treated according to the same rules. These rules should be independent from treatment or outcome. In consequence, the decision to exclude a subject from the statistical analysis must be made before bioanalysis.

In principle any reason for exclusion is valid provided it is specified in the protocol and the decision to exclude is made before bioanalysis. However the exclusion of data should be avoided, as the power of the study will be reduced and a minimum of 12 evaluable subjects is required.

Examples of reasons to exclude the results from a subject in a particular period are events such as vomiting and diarrhoea which could render the plasma concentration-time profile unreliable. In exceptional cases, the use of concomitant medication could be a reason for excluding a subject.

The permitted reasons for exclusion must be pre-specified in the protocol. If one of these events occurs it should be noted in the CRF as the study is being conducted. Exclusion of subjects based on these pre-specified criteria should be clearly described and listed in the study report.

Exclusion of data cannot be accepted on the basis of statistical analysis or for pharmacokinetic reasons alone, because it is impossible to distinguish the formulation effects from other effects influencing the pharmacokinetics.

The exceptions to this are:

1) A subject with lack of any measurable concentrations or only very low plasma concentrations for reference medicinal product. A subject is considered to have very low plasma concentrations if its AUC is less than
5% of reference medicinal product geometric mean AUC (which should be calculated without inclusion of data from the outlying subject). The exclusion of data due to this reason will only be accepted in exceptional cases and may question the validity of the trial;

2) Subjects with non-zero pre-dose concentrations > 5% of Cmax. Such data should be excluded from bioequivalence calculation (see carry-over effects below).

The above can, for immediate release formulations, be the result of subject non-compliance and an insufficient wash-out period, respectively, and should as far as possible be avoided by mouth check of subjects after intake of study medication to ensure the subjects have swallowed the study medication and by designing the study with a sufficient wash-out period. The samples from subjects excluded from the statistical analysis should still be assayed and the results listed (see Presentation of data below).

As stated in section 3.1.4, AUC_{(0-t)} should cover at least 80% of AUC_{(0-∞)}. Subjects should not be excluded from the statistical analysis if AUC_{(0-t)} covers less than 80% of AUC_{(0-∞)}, but if the percentage is less than 80% in more than 20% of the observations then the validity of the study may need to be discussed. This does not apply if the sampling period is 72 h or more and AUC_{(0-72h)} is used instead of AUC_{(0-t)}.

Parameters to be analysed and acceptance limits

In studies to determine bioequivalence after a single dose, the parameters to be analysed are AUC_{(0-t)} or, when relevant, AUC_{(0-72h)} and C_{max}. For these parameters, the 90% confidence interval for the ratio of the test and reference products should be contained within the acceptance interval of 80.00-125.00%.

For studies to determine bioequivalence of immediate release formulations at steady state, AUC_{(0-τ)} and C_{max,ss} should be analysed using the same acceptance interval as stated above.

In the rare case where urinary data has been used, Ae_{(0-t)} should be analysed using the same acceptance interval as stated above for AUC_{(0-t)}. R_{max} should be analysed using the same acceptance interval as for C_{max}.

A statistical evaluation of t_{max} is not required. However, if rapid release is claimed to be clinically relevant and of importance for onset of action or is related to adverse
events, there should be no apparent difference in median tmax and its variability between test and reference product.

In specific cases of products with a narrow therapeutic range, the acceptance interval for AUC may need to be tightened (see section 3.1.9). Moreover, for highly variable drug products the acceptance interval for Cmax may in certain cases be widened (see section 3.1.10).

**Statistical analysis**

The assessment of bioequivalence is based upon 90% confidence intervals for the ratio of the population geometric means (test/reference) for the parameters under consideration. This method is equivalent to two one-sided tests with the null hypothesis of bioinequivalence at the 5% significance level.

The pharmacokinetic parameters under consideration should be analysed using ANOVA. The data should be transformed prior to analysis using a logarithmic transformation. A confidence interval for the difference between formulations on the log-transformed scale is obtained from the ANOVA model. This confidence interval is then back-transformed to obtain the desired confidence interval for the ratio on the original scale. A non-parametric analysis is not acceptable.

The precise model to be used for the analysis should be pre-specified in the protocol. The statistical analysis should take into account sources of variation that can be reasonably assumed to have an effect on the response variable. The terms to be used in the ANOVA model are usually sequence, subject within sequence, period and formulation. Fixed effects, rather than random effects, should be used for all terms.

**Carry-over effects**

A test for carry-over is not considered relevant and no decisions regarding the analysis (e.g. analysis of the first period only) should be made on the basis of such a test. The potential for carry-over can be directly addressed by examination of the pre-treatment plasma concentrations in period 2 (and beyond if applicable).

If there are any subjects for whom the pre-dose concentration is greater than 5 percent of the Cmax value for the subject in that period, the statistical analysis should be performed with the data from that subject for that period excluded. In a 2-period trial this will result in the subject being removed from the analysis.
The trial will no longer be considered acceptable if these exclusions result in fewer than 12 subjects being evaluable. This approach does not apply to endogenous drugs.

**Two-stage design**

It is acceptable to use a two-stage approach when attempting to demonstrate bioequivalence. An initial group of subjects can be treated and their data analysed. If bioequivalence has not been demonstrated, an additional group can be recruited and the results from both groups combined in a final analysis. If this approach is adopted, appropriate steps must be taken to preserve the overall type I error of the experiment and the stopping criteria should be clearly defined prior to the study. The analysis of the first stage data should be treated as an interim analysis and both analyses conducted at adjusted significance levels (with the confidence intervals accordingly using an adjusted coverage probability which will be higher than 90%). For example, using 94.12% confidence intervals for both the analysis of stage 1 and the combined data from stage 1 and stage 2 would be acceptable, but there are many acceptable alternatives and the choice of how much alpha to spend at the interim analysis is at the company’s discretion. The plan to use a two-stage approach must be pre-specified in the protocol along with the adjusted significance levels to be used for each of the analyses.

When analysing the combined data from the two stages, a term for stage should be included in the ANOVA model.

**Presentation of data**

Refer to APPENDIX IV (ASEAN Bioequivalence Study Reporting Format)

**3.1.9 Narrow therapeutic index drugs**

In specific cases of products with a narrow therapeutic index, the acceptance interval for AUC should be tightened to 90.00-111.11%. Where \( C_{\text{max}} \) is of particular importance for safety, efficacy or drug level monitoring the 90.00 — 111.11% acceptance interval should also be applied for this parameter. It is not possible to define a set of criteria to categorise drugs as narrow therapeutic index drugs (NTIDs) and it must be decided case by case if an active substance is an NTID based on clinical considerations.
Highly variable drugs or drug products (HVDP) are those whose intra-subject variability for a parameter is larger than 30%. If an applicant suspects that a drug product can be considered as highly variable in its rate and/or extent of absorption, a replicate crossover design study can be carried out.

Those HVDP for which a wider difference in $C_{\text{max}}$ is considered clinically irrelevant based on a sound clinical justification can be assessed with a widened acceptance range. If this is the case, the acceptance criteria for $C_{\text{max}}$ can be widened to a maximum of 69.84 — 143.19%. For the acceptance interval to be widened, the bioequivalence study must be of a replicate design where it has been demonstrated that the within-subject variability for $C_{\text{max}}$ of the reference compound in the study is $> 30\%$. The applicant should justify that the calculated intra-subject variability is a reliable estimate and that it is not the result of outliers.

The request for widened interval must be prospectively specified in the protocol.

The extent of the widening of $C_{\text{max}}$ criteria follows the table as below:

<table>
<thead>
<tr>
<th>Within-subject CV (%)</th>
<th>Lower Limit</th>
<th>Upper Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>80.00</td>
<td>125.00</td>
</tr>
<tr>
<td>35</td>
<td>77.23</td>
<td>129.48</td>
</tr>
<tr>
<td>40</td>
<td>74.62</td>
<td>134.02</td>
</tr>
<tr>
<td>45</td>
<td>72.15</td>
<td>138.59</td>
</tr>
<tr>
<td>$\geq$ 50</td>
<td>69.84</td>
<td>143.19</td>
</tr>
</tbody>
</table>

$*CV\% = 100 \sqrt{e^{\sigma^2_{WR}}} - 1$

The geometric mean ratio (GMR) should lie within the conventional acceptance range 80.00 — 125.00%.

The possibility to widen the acceptance criteria based on high intra-subject variability does not apply to AUC where the acceptance range should remain at 80.00 — 125.00% regardless of variability.

It is acceptable to apply either a 3-period or a 4-period crossover scheme in the replicate design study.
3.2 *In vitro* dissolution tests

General aspects of in vitro dissolution experiments are briefly outlined in Appendix I including basic requirements how to use the similarity factor ($f^2$-test).

### 3.2.1 *In vitro* dissolution tests complementary to bioequivalence studies

The results of *in vitro* dissolution tests at three different buffers (normally pH 1.2, 4.5 and 6.8) and the media intended for drug product release (QC media, if applicable and available), obtained with the batches of test and reference products that were used in the bioequivalence study should be reported. Particular dosage forms like ODT (oral dispersible tablets) may require investigations using different experimental conditions. The results should be reported as profiles of percent of labelled amount dissolved versus time displaying mean values and summary statistics.

Unless otherwise justified, the specifications for the in vitro dissolution to be used for quality control of the product should be derived from the dissolution profile of the test product batch that was found to be bioequivalent to the comparator product (see Appendix I).

In the event that the results of comparative in vitro dissolution of the biobatches do not reflect bioequivalence as demonstrated in vivo the latter prevails.

However, possible reasons for the discrepancy should be addressed and justified.

### 3.2.2 *In vitro* dissolution tests in support of biowaiver of strengths

Appropriate in vitro dissolution should confirm the adequacy of waiving additional in vivo bioequivalence testing. Accordingly, dissolution should be investigated at different pH values as outlined in the previous section (normally pH 1.2, 4.5 and 6.8) unless otherwise justified. Similarity of in vitro dissolution (see App. I) should be demonstrated at all conditions within the applied product series, i.e. between additional strengths and the strength(s) (i.e. batch(es)) used for bioequivalence testing.

At pH values where sink conditions may not be achievable for all strengths in vitro dissolution may differ between different strengths. However, the comparison with the respective strength of the reference medicinal product should then confirm that this finding is drug substance rather than formulation related. In addition, the applicant could show similar profiles at the same dose (e.g. as a possibility two tablets of 5 mg versus one tablet of 10 mg could be compared).
3.3 Study report

3.3.1 Bioequivalence study report

The report of the bioequivalence study should give the complete documentation of its protocol, conduct and evaluation. It should be written in accordance with APPENDIX IV (ASEAN Bioequivalence Study Reporting Format) and be signed by the investigator. The responsible investigator(s), if any, should sign for their respective sections of the report.

Names and affiliations of the responsible investigator(s), the site of the study and the period of its execution should be stated. Audits certificate(s), if available, should be included in the report.

The study report should include the reference product name, strength, dosage form, batch number, manufacturer, expiry date and country of purchase.

The name and composition of the test product(s) used in the study should be provided. The batch size, batch number, manufacturing date and, if possible, the expiry date of the test product should be stated.

Certificates of analysis of reference and test batches used in the study should be included in an appendix to the study report.

Concentrations and pharmacokinetic data and statistical analyses should be presented in detail.

3.3.2 Other data to be included in an application

The applicant should submit a signed statement confirming that the test product has the same quantitative composition and is manufactured by the same process as the one submitted for authorisation. A confirmation whether the test product is already scaled-up for production should be submitted. Comparative dissolution profiles (see section 3.2) should be provided.
Data sufficiently detailed to enable the pharmacokinetics and the statistical analysis to be repeated, e.g. data on actual times of blood sampling, drug concentrations, the values of the pharmacokinetic parameters for each subject in each period and the randomisation scheme, should be available in a suitable electronic format (e.g. as comma separated and space delimited text files or Excel format) to be provided upon request.

3.4 Variation applications

If a product has been reformulated from the formulation initially approved or the manufacturing method has been modified in ways that may impact on the bioavailability, an in vivo bioequivalence study is required, unless otherwise justified. Any justification presented should be based upon general considerations, e.g. as per APPENDIX III, or on whether an acceptable in vitro / in vivo correlation has been established.

In cases where the bioavailability of the product undergoing change has been investigated and an acceptable correlation between in vivo performance and in vitro dissolution has been established, the requirements for in vivo demonstration of bioequivalence can be waived if the dissolution profile in vitro of the new product is similar to that of the already approved medicinal product under the same test conditions as used to establish the correlation (see APPENDIX I).

When variations to a generic product are made, the comparative medicinal product for the bioequivalence study should normally be a current batch of the reference medicinal product. If a valid reference medicinal product is not available on the market, comparison to the previous formulation (of the generic product) could be accepted, if justified. For variations that do not require a bioequivalence study, the advice and requirements stated in other published regulatory guidance should be followed.

DEFINITIONS

Pharmaceutical equivalence

Medicinal products are pharmaceutically equivalent if they contain the same amount of the same active substance(s) in the same dosage forms that meet the same or comparable standards.
Pharmaceutical equivalence does not necessarily imply bioequivalence as differences in the excipients and/or the manufacturing process can lead to faster or slower dissolution and/or absorption.

**Pharmaceutical alternatives**

Pharmaceutical alternatives are medicinal products with different salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of an active moiety, or which differ in dosage form or strength.

**Pharmacokinetic parameters**

\[
\begin{align*}
A_{e(0-t)} & : \text{Cumulative urinary excretion of unchanged drug from administration until time t;} \\
AUC_{(0-t)} & : \text{Area under the plasma concentration curve from administration to last observed concentration at time t;} \\
AUC_{(0-\infty)} & : \text{Area under the plasma concentration curve extrapolated to infinite time;} \\
AUC_{(0-t)} & : \text{AUC during a dosage interval at steady state;} \\
AUC_{(0-72h)} & : \text{Area under the plasma concentration curve from administration to 72h;} \\
C_{max} & : \text{Maximum plasma concentration;} \\
C_{max,ss} & : \text{Maximum plasma concentration at steady state;} \\
\text{residual area} & : \text{Extrapolated area } (AUC(0-\infty) - AUC(0-t)) / AUC(0-\infty); \\
R_{max} & : \text{Maximal rate of urinary excretion;} \\
t_{max} & : \text{Time until Cmax is reached;} \\
t_{max,ss} & : \text{Time until Cmax,ss is reached;} \\
t_{1/2} & : \text{Plasma concentration half-life;} \\
\lambda_z & : \text{Terminal rate constant;} \\
\text{SmPC} & : \text{Summary of Product Characteristics.}
\end{align*}
\]
APPENDIX I

Dissolution testing and Similarity of Dissolution Profiles

1. General aspects of dissolution testing as related to bioavailability

During the development of a medicinal product a dissolution test is used as a tool to identify formulation factors that are influencing and may have a crucial effect on the bioavailability of the drug. As soon as the composition and the manufacturing process are defined a dissolution test is used in the quality control of scale-up and of production batches to ensure both batch-to-batch consistency and that the dissolution profiles remain similar to those of pivotal clinical trial batches. Furthermore, in certain instances a dissolution test can be used to waive a bioequivalence study. Therefore, dissolution studies can serve several purposes:

i — Testing on product quality

- To get information on the test batches used in bioequivalence studies and pivotal clinical studies to support specifications for quality control
- To be used as a tool in quality control to demonstrate consistency in manufacture
- To get information on the reference product used in bioavailability/bioequivalence studies and pivotal clinical studies.

ii — Bioequivalence surrogate inference

- To demonstrate in certain cases similarity between different formulations of an active substance and the reference medicinal product (biowaivers e.g., variations, formulation changes during development and generic medicinal products; see section 3.2 and App III)
- To investigate batch to batch consistency of the products (test and reference) to be used as basis for the selection of appropriate batches for the in vivo study.

Test methods should be developed product related based on general and/or specific pharmacopoeial requirements. In case those requirements are shown to be unsatisfactory and/or do not reflect the in vivo dissolution (i.e. biorelevance) alternative
methods can be considered when justified that these are discriminatory and able to
differentiate between batches with acceptable and non-acceptable performance of
the product in vivo. Current state-of—the-art information including the interplay of
characteristics derived from the BCS classification and the dosage form must always
be considered.

Sampling time points should be sufficient to obtain meaningful dissolution profiles,
and at least every 15 minutes. More frequent sampling during the period of greatest
change in the dissolution profile is recommended. For rapidly dissolving products,
where complete dissolution is within 30 minutes, generation of an adequate profile by
sampling at 5- or 10-minute intervals may be necessary.

If an active substance is considered highly soluble, it is reasonable to expect that it
will not cause any bioavailability problems if, in addition, the dosage system is rapidly
dissolved in the physiological pH-range and the excipients are known not to affect
bioavailability. In contrast, if an active substance is considered to have a limited or low
solubility, the rate limiting step for absorption may be dosage form dissolution. This is
also the case when excipients are controlling the release and subsequent dissolution
of the active substance. In those cases a variety of test conditions is recommended
and adequate sampling should be performed.

2. Similarity of dissolution profiles

Dissolution profile similarity testing and any conclusions drawn from the results (e.g.
justification for a biowaiver) can be considered valid only if the dissolution profile has
been satisfactorily characterised using a sufficient number of time points.

For immediate release formulations, further to the guidance given in section 1 above,
comparison at 15 min is essential to know if complete dissolution is reached before
gastric emptying.

Where more than 85% of the drug is dissolved within 15 minutes, dissolution profiles
may be accepted as similar without further mathematical evaluation.

In case more than 85% is not dissolved at 15 minutes but within 30 minutes, at least
three time points are required: the first time point before 15 minutes, the second one at
15 minutes and the third time point when the release is close to 85%.

For modified release products, the advice given in the relevant guidance should be
followed.
Dissolution similarity may be determined using the \( f_2 \) statistic as follows:

\[
f_2 = 50 \log \left( \frac{100}{\sqrt{\sum_{t=1}^{n} \left[ R_t - T_t \right]^2 / n}} \right)
\]

In this equation \( f_2 \) is the similarity factor, \( n \) is the number of time points, \( R(t) \) is the mean percent reference drug dissolved at time \( t \) after initiation of the study; \( T(t) \) is the mean percent test drug dissolved at time \( t \) after initiation of the study. For both the reference and test formulations, percent dissolution should be determined.

The evaluation of the similarity factor is based on the following conditions:

- A minimum of three time points (zero excluded);
- The time points should be the same for the two formulations;
- Twelve individual values for every time point for each formulation;
- Not more than one mean value of > 85% dissolved for any of the formulations;
- The relative standard deviation or coefficient of variation of any product should be less than 20% for the first point and less than 10% from second to last time point.

An \( f_2 \) value between 50 and 100 suggests that the two dissolution profiles are similar.

When the \( f_2 \) statistic is not suitable, then the similarity may be compared using model-dependent or model-independent methods e.g. by statistical multivariate comparison of the parameters of the Weibull function or the percentage dissolved at different time points.

Alternative methods to the \( f_2 \) statistic to demonstrate dissolution similarity are considered acceptable, if statistically valid and satisfactorily justified.
The similarity acceptance limits should be pre-defined and justified and not be greater than a 10% difference. In addition, the dissolution variability of the test and reference product data should also be similar, however, a lower variability of the test product may be acceptable.

Evidence that the statistical software has been validated should also be provided. A clear description and explanation of the steps taken in the application of the procedure should be provided, with appropriate summary tables.

**APPENDIX II**

**Bioequivalence study requirements for different dosage forms**

Although this guideline concerns immediate release formulations, Appendix II provides some general guidance on the bioequivalence data requirements for other types of formulations and for specific types of immediate release formulations.

When the test product contains a different salt, ester, ether, isomer, mixture of isomers, complex or derivative of an active substance than the reference medicinal product, bioequivalence should be demonstrated in in vivo bioequivalence studies. However, when the active substance in both test and reference products is identical (or contain salts with similar properties as defined in Appendix III, section III), in vivo bioequivalence studies may in some situations not be required as described below and in Appendix III.

**Oral immediate release dosage forms with systemic action**

For dosage forms such as tablets, capsules and oral suspensions, bioequivalence studies are required unless a biowaiver is applicable (see APPENDIX III). For orodispersable tablets and oral solutions specific recommendations apply, as detailed below.

**Orodispensible tablets**

An orodispensible tablet (ODT) is formulated to quickly disperse in the mouth. Placement in the mouth and time of contact may be critical in cases where the active substance also is dissolved in the mouth and can be absorbed directly via the buccal mucosa. Depending on the formulation, swallowing of the e.g. coated substance and subsequent absorption from the gastrointestinal tract also will occur. If it can be demonstrated that the active substance is not absorbed in the oral cavity, but rather
must be swallowed and absorbed through the gastrointestinal tract, then the product might be considered for a BCS based biowaiver (see Appendix III). If this cannot be demonstrated, bioequivalence must be evaluated in human studies.

If the ODT test product is an extension to another oral formulation, a 3-period study is recommended in order to evaluate administration of the orodispersible tablet both with and without concomitant fluid intake. However, if bioequivalence between ODT taken without water and reference formulation with water is demonstrated in a 2-period study, bioequivalence of ODT taken with water can be assumed.

If the ODT is a generic to an approved ODT reference medicinal product, the following recommendations regarding study design apply:

- if the reference medicinal product can be taken with or without water, bioequivalence should be demonstrated without water as this condition best resembles the intended use of the formulation. This is especially important if the substance may be dissolved and partly absorbed in the oral cavity. If bioequivalence is demonstrated when taken without water, bioequivalence when taken with water can be assumed.

- if the reference medicinal product is taken only in one way (e.g. only with water), bioequivalence should be shown in this condition (in a conventional two-way crossover design).

- if the reference medicinal product is taken only in one way (e.g. only with water), and the test product is intended for additional ways of administration (e.g. without water), the conventional and the new method should be compared with the reference in the conventional way of administration (3 treatment, 3 period, 6 sequence design).

In studies evaluating ODTs without water, it is recommended to wet the mouth by swallowing 20 ml of water directly before applying the CDT on the tongue. It is recommended not to allow fluid intake earlier than 1 hour after administration.

Other oral formulations such as orodispersible films, buccal tablets or films, sublingual tablets and chewable tablets may be handled in a similar way as for ODTs. Bioequivalence studies should be conducted according to the recommended use of the product.
Oral solutions

If the test product is an aqueous oral solution at time of administration and contains an active substance in the same concentration as an approved oral solution, bioequivalence studies may be waived. However if the excipients may affect gastrointestinal transit (e.g. sorbitol, mannitol, etc.), absorption (e.g. surfactants or excipients that may affect transport proteins), in vivo solubility (e.g. co-solvents) or in vivo stability of the active substance, a bioequivalence study should be conducted, unless the differences in the amounts of these excipients can be adequately justified by reference to other data. The same requirements for similarity in excipients apply for oral solutions as for Biowaivers (see Appendix III, Section IV.2 Excipients).

In those cases where the test product is an oral solution which is intended to be bioequivalent to another immediate release oral dosage form, bioequivalence studies are required.

Fixed combination dosage forms

Bioequivalence requirements are covered in the “Guideline on Clinical Development of Fixed Combination Medicinal Products”. The possibility for a biowaiver of Fixed Combination Medicinal Products is addressed in Appendix III section V.

Non-oral immediate release dosage forms with systemic action

This section applies to e.g. rectal formulations. In general, bioequivalence studies are required. A biowaiver can be considered in the case of a solution which contains an active substance in the same concentration as an approved solution and with the same qualitative and similar quantitative composition in excipients (conditions under oral solutions may apply in this case).

Parenteral solutions

Bioequivalence studies are generally not required if the test product is to be administered as an aqueous intravenous solution containing the same active substance as the currently approved product. However, if any excipients interact with the drug substance (e.g. complex formation), or otherwise affect the disposition of the drug substance, a bioequivalence study is required unless both products contain the same excipients in very similar quantity and it can be adequately justified that any difference in quantity does not affect the pharmacokinetics of the active substance.
In the case of other parenteral routes, e.g. intramuscular or subcutaneous, and when the test product is of the same type of solution (aqueous or oily), contains the same concentration of the same active substance and the same excipients in similar amounts as the medicinal product currently approved, bioequivalence studies are not required. Moreover, a bioequivalence study is not required for an aqueous parenteral solution with comparable excipients in similar amounts, if it can be demonstrated that the excipients have no impact on the viscosity.

**Liposomal, micellar and emulsion dosage forms for intravenous use**

- **Liposomal formulations:** Pharmacokinetic issues related to liposomal formulations for iv administration require special considerations which are not covered by the present guideline;

- **Emulsions:** emulsions normally do not qualify for a biowaiver. However, emulsion formulations may be considered eligible for a biowaiver where:
  
  (a) the drug product is not designed to control release or disposition;

  (b) the method and rate of administration is the same as the currently approved product.

In these cases, the composition should be qualitatively and quantitatively the same as the currently approved emulsion and satisfactory data should be provided to demonstrate very similar physicochemical characteristics, including size distribution of the dispersed lipid phase, and supported by other emulsion characteristics considered relevant e.g. surface properties, such as Zeta potential and rheological properties.

- **Lipids for intravenous parenteral nutrition** may be considered eligible for a biowaiver if satisfactory data are provided to demonstrate comparable physicochemical characteristics. Differences in composition may be justified taking into consideration the nature and the therapeutic purposes of such dosage forms;

- **Micelle forming formulations:** micelle solutions for intravenous administration may be regarded as ‘complex’ solutions and therefore normally do not qualify for a biowaiver. However, micelle formulations may be considered eligible for a biowaiver where:
(a) rapid disassembly of the micelle on dilution occurs and the drug product is not designed to control release or disposition;

(b) the method and rate of administration is the same as the currently approved product;

(c) the excipients do not affect the disposition of the drug substance.

In these cases, the composition of the micelle infusion, immediately before administration, should be qualitatively and quantitatively the same as that currently approved and satisfactory data should be provided to demonstrate similar physicochemical characteristics. For example, the critical micelle concentration, the solubilisation capacity of the formulation (such as Maximum Additive Concentration), free and bound active substance and micelle size.

This also applies in case of minor changes to the composition quantitatively or qualitatively, provided this does not include any change of amount or type of surfactants.

**Modified release dosage forms with systemic action**

**Modified release oral and transdermal dosage forms**

Requirements for bioequivalence studies in accordance with the specific Guidelines on Modified Release Oral and Transdermal Dosage Forms: Section II (Pharmacokinetic and Clinical Evaluation) (CPMP/EWP/280/96).

**Modified release intramuscular or subcutaneous dosage forms**

For suspensions or complexes or any kind of matrix intended to delay or prolong the release of the active substance for im or so administration, demonstration of bioequivalence follows the rules for extra vascular modified release formulations. e.g. transdermal dosage forms as per corresponding guideline.

**Locally acting locally applied products**

For products for local use (after oral, nasal, pulmonary, ocular, dermal, rectal, vaginal etc. administration) intended to act at the site of application, recommendations can be found in other guidelines (e.g. CPMP/EWP/4151/00 rev 1, CPMP/EWP/239/95).
A waiver of the need to provide equivalence data may be acceptable in the case of solutions, e.g. eye drops, nasal sprays or cutaneous solutions, if the test product is of the same type of solution (aqueous or oily), and contains the same concentration of the same active substance as the medicinal product currently approved. Minor differences in the excipient composition may be acceptable if the relevant pharmaceutical properties of the test product and reference product are identical or essentially similar. Any qualitative or quantitative differences in excipients must be satisfactorily justified in relation to their influence on therapeutic equivalence. The method and means of administration should also be the same as the medicinal product currently approved, unless otherwise justified.

Whenever systemic exposure resulting from locally applied, locally acting medicinal products entails a risk of systemic adverse reactions, systemic exposure should be measured. It should be demonstrated that the systemic exposure is not higher for the test product than for the reference product, i.e. the upper limit of the 90% confidence interval should not exceed the upper bioequivalence acceptance limit 125.00.

Gases

If the product is a gas for inhalation, bioequivalence studies are not required.

APPENDIX III

BCS-based Biowaiver

I. Introduction

The 808 (Biopharmaceutics Classification System) — based biowaiver approach is meant to reduce in vivo bioequivalence studies, i.e., it may represent a surrogate for in vivo bioequivalence. In vivo bioequivalence studies may be exempted if an assumption of equivalence in in vivo performance can be justified by satisfactory in vitro data.

Applying for a BCS-based biowaiver is restricted to highly soluble drug substances with known human absorption and considered not to have a narrow therapeutic index (see section 3.1.9). The concept is applicable to immediate release, solid pharmaceutical products for oral administration and systemic action having the same dosage form. However, it is not applicable for sublingual, buccal, and modified release formulations. For orodispersible formulations the BCS-based biowaiver approach may only be applicable when absorption in the oral cavity can be excluded.
It is recommended to clarify with the regulatory authorities regarding the implementation of BCS-based biowaiver in the respective countries.

II. Summary Requirements

BCS-based biowaiver are applicable for an immediate release drug product if:

- the drug substance has been proven to exhibit high solubility and complete absorption (BCSclass I; for details see section III.1 and III.2) and;

- either very rapid (> 85 % within 15 min) or similarly rapid (85 % within 30 min) in vitro dissolution characteristics of the test and reference product has been demonstrated considering specific requirements (see section IV.1) and;

- excipients that might affect bioavailability are qualitatively and quantitatively the same. In general, the use of the same excipients in similar amounts is preferred (see section IV.2).

Generally the risks of an inappropriate biowaiver decision should be critically reviewed. (e.g. site-specific absorption, risk for transport protein interactions at the absorption site, excipient composition and therapeutic risks).

III. Drug Substance

Generally, sound peer-reviewed literature may be acceptable for known compounds to describe the drug substance characteristics of importance for the biowaiver concept.

Biowaiver may be applicable when the active substance(s) in test and reference products are identical. Biowaiver may also be applicable if test and reference contain different salts provided that both belong to BCS-class I (high solubility and complete absorption; see sections III.1 and III.2). Biowaiver is not applicable when the test product contains a different ester, ether, isomer, mixture of isomers, complex or derivative of an active substance from that of the reference product, since these differences may lead to different bioavailabilities not deducible by means of experiments used in the BCS-based biowaiver concept.

The drug substance should not belong to the group of ‘narrow therapeutic index’ drugs (see section 3.1.9 on narrow therapeutic index drugs).
III.1 Solubility

The pH-solubility profile of the drug substance should be determined and discussed. The drug substance is considered highly soluble if the highest single dose administered as immediate release formulation(s) is completely dissolved in 250 ml of buffers within the range of pH 1 — 6.8 at 37±1 °C. This demonstration requires the investigation in at least three buffers within this range (preferably at pH 1.2, 4.5 and 6.8) and in addition at the pKa, if it is within the specified pH range. Replicate determinations at each pH condition may be necessary to achieve an unequivocal solubility classification (e.g. shake-flask method or other justified method). Solution pH should be verified prior and after addition of the drug substance to a buffer.

III.2 Absorption

The demonstration of complete absorption in humans is preferred for BCS-based biowaiver applications. For this purpose complete absorption is considered to be established where measured extent of absorption is ≥ 85 %. Complete absorption is generally related to high permeability.

Complete drug absorption should be justified based on reliable investigations in human. Data from:

- absolute bioavailability or;
- mass-balance.

Studies could be used to support this claim.

When data from mass balance studies are used to support complete absorption, it must be ensured that the metabolites taken into account in determination of fraction absorbed are formed after absorption. Hence, when referring to total radioactivity excreted in urine, it should be ensured that there is no degradation or metabolism of the unchanged drug substance in the gastric or intestinal fluid. Phase 1 oxidative and Phase 2 conjugative metabolism can only occur after absorption (i.e. cannot occur in the gastric or intestinal fluid). Hence, data from mass balance studies support complete absorption if the sum of urinary recovery of parent compound and urinary and faecal recovery of Phase 1 oxidative and Phase 2 conjugative drug metabolites account for ≥ 85 % of the dose.
The more restrictive requirements will apply for compounds proposed to be BCS class I but where complete absorption could not convincingly be demonstrated.

Reported bioequivalence between aqueous and solid formulations of a particular compound administered via the oral route may be supportive as it indicates that absorption limitations due to (immediate release) formulation characteristics may be considered negligible. Well performed *in vitro* permeability investigations including reference standards may also be considered supportive to *in vivo* data.

**IV. Drug Product**

**IV.1 In vitro Dissolution**

**IV.1.1 General aspects**

Investigations related to the medicinal product should ensure immediate release properties and prove similarity between the investigative products, i.e. test and reference show similar *in vitro* dissolution under physiologically relevant experimental pH conditions. However, this does not establish an *in vitro* - *in vivo* correlation. *In vitro* dissolution should be investigated within the range of pH 1 — 6.8 (at least pH 1.2, 4.5, and 6.8). Additional investigations may be required at pH values in which the drug substance has minimum solubility. The use of any surfactant is not acceptable.

Test and reference products should meet requirements as outlined in section 3.1.2 of the main guideline text. In line with these requirements it is advisable to investigate more than one single batch of the test and reference products.

Comparative *in vitro* dissolution experiments should follow current compendial standards. Hence, thorough description of experimental settings and analytical methods including validation data should be provided. It is recommended to use 12 units of the product for each experiment to enable statistical evaluation. Usual experimental conditions are e.g.:

- Apparatus: paddle or basket
- Volume of dissolution medium: 900 ml or less
- Temperature of the dissolution medium: 37±1 °C
- Agitation: paddle apparatus - usually 50 rpm, basket apparatus - usually 100 rpm
- Sampling schedule: e.g. 10, 15, 20, 30 and 45 min
- Buffer: pH 1.0 — 1.2 (usually 0.1 N HCl or SGF without enzymes), pH 4.5,
and pH 6.8 (or SIF without enzymes); (pH should be ensured throughout the experiment; Ph.Eur. buffers recommended)

- Other conditions: no surfactant; in case of gelatin capsules or tablets with gelatin coatings the use of enzymes may be acceptable.

Complete documentation of in vitro dissolution experiments is required including a study protocol, batch information on test and reference batches, detailed experimental conditions, validation of experimental methods, individual and mean results and respective summary statistics.

IV.1.2 Evaluation of in vitro dissolution results

Drug products are considered ‘very rapidly’ dissolving when more than 85% of the labelled amount is dissolved within 15 min. In cases where this is ensured for the test and reference product the similarity of dissolution profiles may be accepted as demonstrated without any mathematical calculation.

Absence of relevant differences (similarity) should be demonstrated in cases where it takes more than 15 min but not more than 30 min to achieve almost complete (at least 85% of labelled amount) dissolution. Fₙ-testing (see App. I) or other suitable tests should be used to demonstrate profile similarity of test and reference. However, discussion of dissolution profile differences in terms of their clinical/therapeutical relevance is considered inappropriate since the investigations do not reflect any in vitro/in vivo correlation.

IV.2 Excipients

Although the impact of excipients in immediate release dosage forms on bioavailability of highly soluble and completely absorbable drug substances (i.e., BCS-class I) is considered rather unlikely, it cannot be completely excluded. Therefore, even in the case of class I drugs it is advisable to use similar amounts of the same excipients in the composition of test like in the reference product.

As a general rule, for BCS-class I drug substances, well-established excipients in usual amounts should be employed and possible interactions affecting drug bioavailability and/or solubility characteristics should be considered and discussed. A description of the function of the excipients is required with a justification whether the amount of each excipient is within the normal range. Excipients that might affect bioavailability, like e.g. sorbitol, mannitol, sodium lauryl sulfate or other surfactants, should be identified as
well as their possible impact on:

- gastrointestinal motility;
- susceptibility of interactions with the drug substance (e.g. complexation);
- drug permeability;
- interaction with membrane transporters.

Excipients that might affect bioavailability should be qualitatively and quantitatively the same in the test product and the reference product.

V. Fixed Combinations (FCs)

BCS-based biowaiver are applicable for immediate release FC products if all active substances in the FC belong to BCS-class I and the excipients fulfil the requirements outlined in section IV.2. Otherwise in vivo bioequivalence testing is required.

APPENDIX IV

ASEANBioequivalence Study Reporting Format

1. Title Page

1.1 Study Title;
1.2 Name and address of Sponsor;
1.3 Name, person in charge and address of Institution;
1.4 Name and address of Principal Investigator;
1.5 Name of Medical/Clinical Investigator;
1.6 Name, person in charge and address of clinical laboratory;
1.7 Name, person in charge and address of analytical laboratory;
1.8 Name, person in charge and address for Data Management, Pharmacokinetics and Statistical Analysis;
1.9 Name and address of Other Investigator(s) & study personnel;
1.10 Staff and end date of clinical and analytical study;
1.11 Signature and date of investigator(s), (medical writer, QA Manager — if applicable).

2. Study Synopsis

3. Table of Contents
4. Abbreviation and Definition of Terms

5. Introduction

5.1 Pharmacology;
5.2 Pharmacokinetics;
5.3 Adverse events.

6. Objective

7. Product Information

7.1 Test Product Information
- Trade Name;
- Active Ingredient, Strength, and Dosage Form;
- Batch Number, Manufacturing Date and Expiry Date;
- Batch size compliance (can be directly provided by sponsor);
- Product Formulation (can be directly provided by sponsor);
- Finished Product Specifications (can be directly provided by sponsor);
- Name and Address of Manufacturer.

7.2 Comparator Product Information
- Trade Name;
- Active Ingredient, Strength, and Dosage Form;
- Batch Number, Manufacturing Date and Expiry Date;
- Name and Address of Manufacturer;
- Name and Address of Importer or Authorization Holder.

7.3 Pharmaceutical Equivalence Data
- Comparing content of Active Ingredient / Potency;
- Uniformity of Dosage Units.

7.4 Comparison of Dissolution Profiles (can be directly provided by sponsor).

7.5 Letter with a signed statement from the applicant/sponsor confirming that the test product is the same as the one that is submitted for marketing authorization.

8. Investigational Plan
8.1 Clinical Study Design
- Study design (crossover, parallel);
- Fed, fasted;
- Inclusion, exclusion, restriction;
- Standardization of study condition;
- Drug administration;
- Removal of Subject from Assessment;
- Health screening;
- Subject detail, no of subjects, deviation;
- Sampling protocol/time, sample preparation/handling, storage, deviation;
- Volume of blood collected;
- Subject monitoring;
- Genetic phenotyping (if applicable).

8.2 Study Treatments
- Selection of Doses — single, multiple;
- Identity of Investigational Products, dosing;
- Randomization;
- Blinding;
- Washout period;
- Water intake volume.

8.3 Clinical and Safety Records
- Adverse Event;
- Drug related Adverse Drug Reaction.

8.4 Pharmacokinetic Parameters and Tests
- Definitions and calculation.

8.5 Statistical Analyses
- Log transformed data analysis (AUC, Cmax);
- Sampling Time Adjustments;
- t max,;
- t1/2;
- Acceptance Criteria for Bioequivalence;
- ANOVA presentation;
- Power.

8.6 Assay Methodology and Validation
- Assay method description;
- Method of detection;
- Validation procedure and summary results.
  • Specificity;
  • Accuracy;
  • Precision;
  • Recovery;
  • Stability;
  • LOQ;
  • Linearity.

8.7 Data Quality Assurance

9. Results and Discussion

9.1 Clinical Study Results
- Demographic characteristics of the subjects;
- Details of clinical activity;
- Deviation from protocol, if any;
- Results of drug/alcohol/smoking usage, medical history and medical examination, vital sign and diagnostic laboratory test of subjects;
- Adverse event/reaction reports for test product and comparator product.

9.2 Summary of analytical results

9.3 Pharmacokinetic Analyses
- Drug levels at each sampling time, descriptive statistics;
- Table of individual subject pharmacokinetic parameters, descriptive statistics;
- Figure of mean plasma or urine concentration-time profile;
- Figure of individual subject plasma or urine concentration-time profile.

9.4 Statistical Analyses
- Statistical considerations;
- Time points selected for Kel, t_{1/2};
- Summary statistics of pharmacokinetic parameters: AUC_{t}, % AUC extrapolated, AUC_{ref}, C_{max}, t_{max}, t_{1/2};
- Summary of statistical significance for AUC and C_{max} (based on log-transformed data calculated as point estimate and 90 % CI of test/comparator Geometric Means) and for t_{max} (based on non-transformed data calculated as p value);
- Similar calculation for urine data: \( A_e \) and \( dA_e/dt \) (\( A_e \) corresponds to AUC, \( (dA_e/dt)_{max} \) corresponds to \( C_{max} \));
- Intra-subject variability;
- Power of study;
- Assessment of sequence, period and treatment effects;
- Table — Analysis of Variance, Geometric least-squares means for each pharmacokinetic parameters;
- Table — Calculation of 90% confidence interval for the ratio of pharmacokinetic parameters under consideration in logarithmic transformation.

10. Conclusions

11. Appendices

11.1 Protocol and Approval
- Letter of approval from DRA (if applicable);
- Study protocol and its amendments together with Institutional;
- Review Board/Ethical Committee approvals;
- Informed Consent Form;
- Protocol deviation listing;
- Adverse Event listing;
- FP specification and CoA.

11.2 Validation Report (including 20% of raw chromatograms).

11.3 Analytical Report (including 20% of raw chromatograms).

11.4 Certificate of Clinical Facility, Clinical Laboratory and Certificate of Analytical Laboratory (if any).

11.5 Dose proportionality comparative dissolution profiles between various strengths (when BE study investigating only one strength but application for registration consists of several strengths (from sponsor).
For inquiries, contact:
The ASEAN Secretariat
70 A Jalan Sisingamangaraja
Jakarta 12110
Indonesia

Phone  : (+6221) 724-3372, 726-2991
Fax    : (+6221) 739-8234, 724-3504
E-mail : public@asean.org

This is supported by the European Union through the ASEAN Regional Integration Support from the EU (ARISE Plus).